Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
NCT03037437
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Cancer
Interventions
DRUG:
Sorafenib (SOR)
DRUG:
Hydroxychloroquine (HCQ)
Sponsor
The University of Texas Health Science Center at San Antonio